RxDoctor Payments Data

Vijay Mittal, MD

Cardiovascular Disease · Ocala, FLNPI 1821026022

Payments from drug & device makers

$3,301in general payments, 2019–2025

Across 91 payments — averaging $36.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$535
  • Abbott$411
  • Johnson & Johnson$314
  • Amgen$276
  • Abiomed$273
  • Pfizer$255
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,287100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,301 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$486,228
Medicare patients
1,000
Services billed
4,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban413$467,202
XareltoRivaroxaban136$162,519
EntrestoSacubitril/Valsartan72$104,057
JardianceEmpagliflozin36$34,162
Repatha SureclickEvolocumab55$32,666
FarxigaDapagliflozin Propanediol20$21,978
OzempicSemaglutide18$17,268
Metoprolol Succinate517$7,302
Atorvastatin Calcium476$5,131
Losartan Potassium375$4,606
Prasugrel Hcl13$4,451
Diltiazem Hcl82$3,979
Amiodarone Hcl101$3,105
Amlodipine Besylate479$3,104
Metoprolol Tartrate312$2,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$255$467,202413 claims
Johnson & JohnsonXarelto$314$162,519136 claims
NovartisEntresto$535$104,05772 claims
Boehringer IngelheimJardiance$57$34,16236 claims
AstraZenecaFarxiga$183$21,97820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →